A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 17 Apr 2020 Status changed from active, no longer recruiting to completed.
- 14 Feb 2020 Planned End Date changed from 31 Dec 2019 to 28 Feb 2020.
- 14 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 28 Feb 2020.